Back

Beyond body mass index: consistent benefits of sodium–glucose cotransporter 2 inhibitors and the limits of a convenient metric

European Heart Journal - Quality of Care and Clinical Outcomes

23 May 2026
Organised by: Logo
Read full article
ESC Journals CARDIOVASCULAR PHARMACOLOGY

Contributors

Martina Chiriacò
Martina Chiriacò

Author

University Hospital of Pisa Pisa , Italy

Vincenzo Castiglione
Vincenzo Castiglione

Author

Fondazione Toscana Gabriele Monasterio Pisa , Italy

Michele Emdin
Michele Emdin

Author

You may be interested in
thumbnail
Congress Session
Diabetes, obesity, and heart failure
19 May 2025
thumbnail
Congress Presentation
Risk of death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials: an updated meta-analysis
27 August 2021
thumbnail
Congress Session
Novel weight loss strategies to reduce cardiovascular risk in obesity
25 August 2023
thumbnail
Congress Presentation
Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study
9 December 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources